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Background Basal cell carcinoma (BCC) is the most common cancer affecting
white-skinned individuals, and the worldwide incidence is increasing. Although
rarely fatal, BCC is associated with significant morbidity and costs.
Objectives To assess the effects of interventions for primary BCC in immunocompe-
tent adults.
Methods We updated our searches of the following databases to November 2019:
Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL
and LILACS. Certainty of evidence was assessed using the Grading of Recommen-
dations Assessment, Development and Evaluation method. We used standard
methodological procedures expected by Cochrane.
Results We included 52 randomized controlled trials with 6990 participants (me-
dian age 65 years; range 20–95). Mean study duration was 13 months (range
6 weeks–10 years). Ninety-two per cent (n = 48/52) of studies exclusively
included histologically low-risk BCC (nodular and superficial subtypes). The cer-
tainty of evidence was predominantly low or moderate for the outcomes of inter-
est. Overall, surgical interventions have the lowest recurrence rates, and there
may be slightly fewer recurrences with Mohs micrographic surgery over surgical
excision for primary, facial BCC (high-risk histological subtype or located in the
‘H-zone’ or both) (low-certainty evidence). Nonsurgical treatments, when used
for low-risk BCC, are less effective than surgical treatments, but recurrence rates
are acceptable and cosmetic outcomes are probably superior.
Conclusions Surgical interventions have lower recurrence rates and remain the gold
standard for high-risk BCC. Of the nonsurgical treatments, topical imiquimod has
the best evidence to support its efficacy for low-risk BCC. Priorities for future
research include agreement on core outcome measures and studies with longer
follow-up.
What is already known about this topic?
• Basal cell carcinoma (BCC) is the most common cancer to affect white-skinned
individuals, and worldwide incidence is increasing.
• A 2007 Cochrane review concluded that there was very little good-quality research
on treatments for BCC and that surgical interventions and radiotherapy had the
lowest recurrence rates.
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What does this study add?
• The body of evidence has now doubled to 52 trials, but most deal with low-risk
lesions.
• The quality of evidence remains generally low to moderate.
• Surgical interventions still have the lowest recurrence rates, and there may be
slightly fewer recurrences with Mohs micrographic surgery over surgical excision
for high-risk facial primary BCC.
• Nonsurgical treatments are less effective than surgery, but recurrence rates are
acceptable for low-risk lesions and cosmetic outcomes are probably superior.
Basal cell carcinoma (BCC) is the most common skin cancer
and the most common cancer found in white-skinned individ-
uals.1–3 BCCs are slow-growing, locally invasive, malignant
(but not life-threatening), epidermal skin tumours.4,5 BCCs
affect the head and neck region around 70% of the time, and
the trunk and extremities around 30% of the time.6 A system-
atic review identified that the incidence of BCC is increasing
in Europe by 55% annually.3 Between 2013 and 2015 there
was a mean annual percentage increase of 5% in BCC inci-
dence across the UK.6
Clinicopathological features are used to differentiate BCCs
into high- and low-risk subtypes, which has implications on
management. High-risk BCCs include morphoeic, infiltrative
and micronodular histological subtypes; the presence of per-
ineural or perivascular invasion; size > 5 cm; a recurrent lesion;
a centrofacial location, including periocular areas and the ears;
and host immunosuppression.2 Low-risk BCCs include superfi-
cial and nodular histological subtypes when they are located at a
low-risk site (e.g. not centrofacial location).
Numerous interventions are available for treating BCC, with
the primary aim of treatment being to remove or destroy the
lesion completely, resulting in cure with minimal risk of
recurrence. Tumour removal should also be balanced against
the patient’s requirement for a good/acceptable cosmetic
result. The first-line treatment of BCC is often surgical excision
(SE) with Mohs micrographic surgery (MMS) reserved for
high-risk sites. Numerous alternatives are available and include
surgery under frozen section margin control; radiotherapy;
photodynamic therapy (PDT); curettage and cautery
(‘electrodesiccation’); cryosurgery (‘cryotherapy’); laser; elec-
trochemotherapy; immunomodulators; topical chemotherapy;
intralesional chemotherapy; systemic chemotherapy; and tar-
geted molecular therapy (hedgehog pathway inhibitors).
This article is a summary of a Cochrane review that evalu-
ated the effects of interventions for BCC,7 providing the best
available evidence to healthcare providers and patients so that
they can weigh up the risks and benefits of treatments, and to
allow and promote shared decision-making.
Materials and methods
We followed the protocol from an earlier version of this
review, which was published in 2003.8 One important
deviation from the original protocol is that we assessed recur-
rence rates at 3 and 5 years separately, whereas previously we
considered all recurrences between 3 and 5 years. The reason
for this change was to ensure that we could detect any impor-
tant differences in recurrences at 3 and 5 years, given that
several studies have reported on longer follow-up data.
Selection criteria
Inclusion criteria were randomized controlled trials (RCTs) of
interventions for BCC in immunocompetent adults with histo-
logically proven primary BCC. Studies that included partici-
pants with Gorlin (basal cell naevus) syndrome, organoid
naevi or other genetic syndromes were excluded. Persistent or
recurrent tumours were excluded. We aimed to identify all
relevant RCTs, regardless of language or publication status.
Outcome measures
Primary outcome measures were recurrence at 3 years and
5 years (measured clinically), and cosmetic outcome (partici-
pant- and observer-rated using any validated method for
assessing cosmetic outcome). We did not prespecify a time-
point for our cosmetic outcome, but aimed to include out-
comes measured after at least 1 year (minimum time taken
for a scar to mature). If multiple timepoints were reported,
we reported the closest timepoint to 1 year (but not less than
1 year). Secondary outcomes measures were pain during treat-
ment and thereafter, early treatment failure (within 6 months,
measured histologically) and adverse effects.
Search strategy
We searched MEDLINE, Embase, the Cochrane Skin Specialised
Register, CENTRAL, CINAHL and LILACS from inception until
19 November 2019. The trial registries ISRCTN, ClinicalTri-
als.gov, the Australian New Zealand Clinical Trials Registry,
International Clinical Trials Registry Platform (ICTRP) and the
EU Clinical Trials Register were searched on 3 March 2019
using the term ‘basal cell carcinoma’. We checked references
from included studies to identify further trials. Details of the
databases and search strategy are available in Table S1 and
Appendices S1–S6 (see Supporting Information). Three
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authors (J.T., S.H., F.J.B.-H.) independently carried out study
selection, and disagreements were resolved by discussion.
Data extraction and risk of bias assessment
Three authors (J.T., S.H., F.J.B.-H.) independently extracted
the data, using a prederived data extraction form. Missing data
were obtained from the trial authors where possible. Any dis-
agreements in study selection or data extraction were resolved
by discussion and/or by involving a fourth author (H.C.W.).
The Cochrane risk-of-bias assessment framework was used to
evaluate the internal validity of studies.9 Two authors (J.T.,
S.H.) independently assessed the risk of bias in included stud-
ies. Any disagreements were resolved through discussion
between the authors, including a third author (H.C.W.).
Data synthesis and statistical analysis
We expressed the results as a risk ratio (RR) with 95% confi-
dence intervals (CIs) for dichotomous outcomes, and differ-
ence in means with 95% CIs for continuous outcomes. For
studies with a similar type of active intervention, we per-
formed a meta-analysis, to calculate a weighted treatment
effect across trials, using a random-effects (DerSimonian and
Laird) model. Where it was not possible to perform a meta-
analysis, we summarized the data for each trial and have only
presented forest plots. If raw data could not be extracted, we
extracted the results from appropriate statistical analyses pre-
sented in the paper and reported these in the review. We con-
sidered a P-value < 005 as statistically significant.
We used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) to assess quality of the
body of evidence separately for each outcome.10
Results
Description of included studies
A total of 52 RCTs (6690 participants) met our inclusion crite-
ria, with 26 studies from the previous review and 26 new stud-
ies (Figure 1).11–67 Table S2 (see Supporting Information)
summarizes the characteristics of all included studies. The med-
ian age of participants was 65 years (range 20–95). There were
more male than female participants (male-to-female ratio 148 :
1). Studies all recruited from secondary care clinics and the aver-
age study duration was 13 months (range 6 weeks–10 years).
The number of participants randomized in each study ranged
from 13 to 724 (median 89 participants). The majority of stud-
ies (n = 48/52) exclusively included BCC of low-risk histologi-
cal subtypes [nodular (nBCC), superficial (sBCC)]. Only four
studies included high-risk histological subtypes.18,20,21,55 Over-
all, 22 studies were industry funded, with studies of imiquimod
and PDT being over-represented in this group.
Studies evaluated 15 categories of surgical and nonsurgical
interventions. The most common comparators were nonsurgi-
cal treatments, with 20 RCTs comparing a nonsurgical
treatment to another nonsurgical treatment. Fourteen RCTs
compared a nonsurgical treatment with placebo. Eighteen
RCTs had a surgical treatment comparator, with 10 RCTs com-
paring a surgical treatment to a nonsurgical treatment, five
RCTs comparing a surgical treatment to a surgical treatment
and three RCTs comparing a surgical treatment to placebo.
Safety was the most commonly evaluated outcome, with
81% of the comparisons assessing adverse effects. Seventy-five
per cent of comparisons assessed early treatment failure, 21%
reported 3-year recurrence, 17% reported 5-year recurrence,
37% reported on cosmetic outcomes (27% had data for analy-
sis) and 46% reported on pain (19% had data for analysis).
Risk of bias within studies
Figure 2 and Figure S1 (see Supporting Information) summa-
rize the risk of bias per domain and per study, respectively. Only
one study was identified as having a high risk of selection bias.51
Only 37% of studies (n = 19) were assessed as being at low risk
of bias for blinding of the outcome assessor. We rated 62% of
studies (n = 32) as having an unclear risk of incomplete out-
come data. Only 12% of studies (n = 6) were deemed at low
risk of selective outcome reporting bias, and only 21% of stud-
ies (n = 11) prospectively registered their RCT.
Effects of interventions
We have presented our primary outcomes for the seven most
important comparisons in this article. This was based on the
study authors’ experiences and an electronic survey sent to
clinicians in our centre, on what were felt to be the most
important outcomes and comparisons to patients and clini-
cians. Tables 1–7 summarize the results of all outcomes (apart
from adverse effects) and the GRADE assessments for these
seven comparisons. Table S3 (see Supporting Information)
provides an explanation of the GRADE Working Group grades.
Mohs micrographic surgery vs. surgical excision
One study compared SE against MMS in 374 participants (408
lesions) with high-risk facial primary BCCs (high-risk histo-
logical subtype and/or located in the ‘H-zone’ of the
face).18,36 The study used 3-mm margins for both treatments
to standardize the two modalities (smaller margins are usually
used for MMS). Our analyses found that there may be slightly
fewer recurrences with MMS vs. SE at 3 years [19% (n = 3/
160) vs. 29% (n = 5/171); RR 064, 95% CI 016–264
(low-certainty evidence)] and at 5 years [32% (n = 4/125)
vs. 52% (n = 7/134); RR 061, 95% CI 018–204 (low-cer-
tainty evidence)] (Table 1).
No significant differences in cosmetic outcomes between
MMS and SE were reported; however, the data were not pre-
sented. The study reported that there was ‘no difference in
post-operative complications between SE and MMS’; however,
raw data were not presented for this outcome to verify this.
See Table 1.
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Imiquimod vs. surgical excision
One study compared imiquimod with SE in 501 participants
with nBCC or sBCC at low-risk sites in a noninferiority
trial design with 5 years of follow-up.41 Imiquimod
probably results in more recurrences (164%, n = 35/213)
than SE (16%, n = 3/188) at 3 years corresponding to a
10-fold increased risk of recurrence with imiquimod [RR
1030, 95% CI 322–3294 (moderate-certainty evidence)].
By 5 years, imiquimod may result in more recur-
rences (175%, n = 36/206) than SE (23%, n = 4/177)
with a nearly eightfold increased risk of recurrence [RR
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) study flow diagram. BCC, basal cell carcinoma; RCT,
randomized controlled trial.
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773, 95% CI 281–2130 (moderate-certainty evidence)]
(Table 2).
When participant-rated, there may be little-to-no difference
between imiquimod (919%, n = 147/160) and SE (922%,
n = 153/166) on the rate of good/excellent cosmetic out-
comes [RR 100, 95% CI 094–106 (low-certainty evidence)].
When rated by a dermatologist, imiquimod may improve the
rate of good/excellent cosmetic outcomes [606% (n = 103/
170) vs. SE 356% (n = 62/174), corresponding to a 70%
increased rate for imiquimod (RR 170, 95% CI 135–215;
low-certainty evidence)].
Radiotherapy vs. surgical excision
One study compared SE (with the option for frozen section
margin control) with radiotherapy in 374 participants with
BCCs < 4 cm diameter on the face (high- and low-risk histo-
logical subtypes).21
At 3 years radiotherapy may lead to increased risk of recur-
rence vs. SE, with recurrence rates of 52% (n = 9/173) and
0% (n = 0/174), respectively [RR 1911, 95% CI 112–
32578 (low-certainty evidence)] (Table 3).
By 4 years, radiotherapy may result in a higher risk of
recurrence than SE, with recurrence rates of 64% (n = 11/
173) and 06% (n = 1/174), respectively [RR 1106, 95% CI
144–8477 (low-certainty evidence)].
Dyspigmentation and telangiectasia occurred in the majority
of patients treated with radiotherapy, and by comparing the
rate of participant-reported good cosmetic outcomes (3-point
scale: bad, fair or good) at 4 years between the groups, radio-
therapy probably worsens the rate of good cosmetic outcome,
compared with SE [RR 076, 95% CI 063–091 (moderate-
Figure 2 Risk-of-bias graph: review authors’ judgements about each risk-of-bias item presented as percentages across all included studies.
Table 1 Mohs micrographic surgery (MMS) vs. surgical excision (SE) for high-risk basal cell carcinomaa
Outcomes








(GRADE) CommentsRisk with SE Risk with MMS










Cosmetic outcome Although a reported outcome,
raw data were not available.
The authors of the study state that,
overall, cosmetic outcomes did not
significantly differ between groups.18,36
The cosmetic outcomes were judged
by participants 18 months postoperatively,
and photographs of a selected group
of tumours (first 139 primary) were
judged retrospectively by a panel
of six individuals
NE (1 RCT) ⊕⊕⊝⊝
LOWc
–
Pain No study addressed this outcome NE – – –
Early treatment failure No study addressed this outcome NE – – –
CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NE, not estimable; RR, risk ratio;
RCT, randomized controlled trial. aPatient or population: adults with high-risk BCC; setting: secondary care with outpatients from hospitals
in the Netherlands; intervention: MMS; comparison: SE. bDowngraded two levels for very serious imprecision due to very wide 95% CI, indi-
cating the possibility of important benefit or harm. cDowngraded two levels for very serious indirectness as although the authors did com-
pare the cosmetic outcomes between the two groups, they did not present the data for analysis.
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certainty evidence)]. At 4 years, radiotherapy probably wors-
ens the rate of dermatologist-assessed cosmesis based on the
scar (bad, clearly marked or slightly visible), compared with
SE [RR 048, 95% CI 037–062 (moderate-certainty evi-
dence)].
Photodynamic therapy vs. surgical excision
Three studies compared PDT with the photosensitizer
methyl aminolaevulinate (MAL) against SE. One study
included nBCC of the face (103 participants; 118 lesions)
with a 5-year follow-up.15,68 Another study included 57
participants (68 lesions) with nBCC in the head and neck
area, with a 3 year follow-up.47 A noninferiority study
included 196 participants with 246 sBCCs (between 8 mm
and 20 mm in diameter located anywhere except mid-face)
with a 1-year follow-up.45 Only one study compared frac-
tionated PDT using the photosensitizer aminolaevulinic acid
(ALA) to SE in 171 primary nBCCs (149 participants) with
5 year follow-up.43
At 3 years, MAL-PDT may increase the risk of recurrence
vs. SE [364% (n = 12/33) vs. 0% (n = 0/35); RR 2647,
95% CI 163–42992 [low-certainty evidence]) (Table 4).
Compared with SE, ALA-PDT probably increases the risk of
recurrence at 3 years [247% (n = 21/85) vs. 23% (n = 2/
88); RR 1087, 95% CI 263–4495 (moderate-certainty evi-
dence)] (Table 5). By 5 years, ALA-PDT probably increases
the risk of recurrence, compared with SE [271% (n = 23/85)
vs. 23% (n = 2/88); RR 1191, 95% CI 290–4895 (moder-
ate-certainty evidence)].
In pooling cosmetic results, we found that, when measured
at 1 year, MAL-PDT probably slightly reduces the rate of par-
ticipant-rated good/excellent cosmetic outcomes, compared
with SE [RR 118, 95% CI 109–127; I2 = 0% (moderate-cer-
tainty evidence)]. When investigator-rated at 1 year, MAL-
PDT probably increases the rate of good/excellent cosmetic
outcomes vs. SE [RR 187. 95% CI 154–226; I2 = 0% (mod-
erate-certainty evidence)].
Imiquimod vs. photodynamic therapy
One study assessed whether fluorouracil (5-FU) cream and
imiquimod cream were noninferior to MAL-PDT in 601 par-
ticipants with a single sBCC (anywhere except high-risk face/
scalp) in a three-arm RCT with 5 years of follow-up.40,59
Compared with MAL-PDT, imiquimod cream probably reduces
Table 2 Imiquimod vs. surgical excision (SE) for low-risk basal cell carcinoma (BCC)a
Outcomes








(GRADE) CommentsRisk with SE
Risk with
imiquimod
Recurrence at 3 years Study population RR 1030
(322–3294)





Recurrence at 5 years Study population RR 773
(281–2130)







Study population RR 100
(094–106)
326 (1 RCT) ⊕⊕⊝⊝
LOWc
Participant-rated at 3 years




Study population RR 170
(135–215)
344 (1 RCT) ⊕⊕⊝⊝
LOWc
Observer-rated at 3 years
on 6-point scaled356/1000 606/1000
(481–766)
Pain (moderate/severe) Study population RR 136
(098–188)





Pain (moderate/severe) Study population RR 047
(029–077)





Early treatment failure No study addressed this outcome NE – – –
CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NE, not estimable; RR, risk ratio;
RCT, randomized controlled trial. aPatient or population: adults with low-risk BCC; setting: secondary care with outpatients from hospitals in
the UK; intervention: 5% imiquimod cream; comparison: SE. bDowngraded one level for serious imprecision as only a single study with a
small sample size and a wide 95% CI. cDowngraded one level for serious imprecision as only a single study with a small sample size and
one level for serious risk of bias as unable to blind truly owing to the nature of interventions (i.e. presence or absence of scar will unblind
to treatment allocation). dSix-point scale: unable to see lesion; very poor; poor; fair; good; excellent. eDowngraded one level for serious
imprecision as only a single study with a small sample size and one level for serious risk of attrition bias as fewer pain data were available
for the SE group. fMeasured on following scale: no pain; mild pain; mild-to-moderate pain; moderate pain; moderate-to-severe pain; and
severe pain.
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the risk of recurrence at 3 years [228% (n = 34/149) vs.
516% (n = 66/128), respectively; RR 044, 95% CI 032–
062 (moderate-certainty evidence)] (Table 6). At 5 years,
imiquimod cream probably reduces the risk of recurrence,
compared with MAL-PDT [286% (n = 36/126) vs. 686%
(n = 70/102), respectively; RR 042, 95% CI 031–057;
moderate-certainty evidence)].
There is probably little-to-no difference between imiqui-
mod and MAL-PDT with regard to the rate of good/excellent
cosmetic outcomes when rated by a blinded observer at 1 year
on a 4-point scale (RR 098, 95% CI 084–116; moderate-
certainty evidence).40,59
Imiquimod cream vs. 5-fluorouracil cream
Compared with 5-FU cream, imiquimod probably reduces the
risk of recurrence at 3 years [342% (n = 34/145) vs. 234%
(n = 50/146), respectively; RR 068, 95% CI 047–099
(moderate-certainty evidence)] (Table 7).40,59 Compared with
5-FU cream, imiquimod probably reduces the risk of recur-
rence at 5 years [460% (n = 36/126) vs. 286% (n = 57/
124), respectively; RR 062, 95% CI 044–087 (moderate-
certainty evidence)].
When blinded observer-rated at 1 year, there is probably
little-to-no difference between imiquimod and 5-FU cream in
the rate of good/excellent cosmetic outcomes [614%
(n = 113/184) vs. 575% (n = 111/193); RR 107, 95% CI
090–126 (moderate-certainty evidence)].40,59
Photodynamic therapy vs. cryosurgery
One study compared MAL-PDT with cryotherapy in 118 par-
ticipants with 219 sBCCs with 5 years of follow-up.31 It
showed there may be little-to-no difference between MAL-
PDT and cryosurgery on the risk of recurrence at 3 years
[22% (n = 22/100) vs. 194% (n = 18/93), respectively; RR
114, 95% CI 065–198 (low-certainty evidence)].
When participant-rated at 1 year on a 4-point scale, MAL-
PDT probably increases the rate of good/excellent cosmetic
outcomes vs. cryosurgery [100% (n = 51/51) vs. 813%
(n = 39/48), respectively; RR 123, 95% CI 107–141 (mod-
erate-certainty evidence)]. When rated by an investigator on a
4-point scale, MAL-PDT probably increases the rate of good/
excellent cosmetic outcomes vs. cryosurgery [89% (n = 45/
51) vs. 61% (n = 29/48); RR 146, 95% CI 114–188 (mod-
erate-certainty evidence)].
Another study compared ALA-PDT with cryotherapy in 88
participants with nBCC and sBCC with only 1 year of follow-
up and we are therefore unable to comment on recurrence
rate.29 The study showed that, compared with cryosurgery,
ALA-PDT probably increases the rate of good/excellent cos-
metic outcomes at 1 year [92.8% (n = 39/42) vs. 54%
Table 3 Radiotherapy vs. surgical excision (SE) for high- and low-risk basal cell carcinoma (BCC)a
Outcomes
Anticipated absolute effects (95% CI)






(GRADE) CommentsRisk with SE
Risk with
radiotherapy












Study population RR 076 (063–091) 347 (1 RCT) ⊕⊕⊕⊝
MODERATEd
Participant-rated















Pain No study addressed this outcome NE – – –
Early treatment failure No study addressed this outcome NE – – –
CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development and Evaluation; ITT, intention to treat; NE, not
estimable; RCT, randomized controlled trial; RR, risk ratio. aPatient or population: adults with high- and low-risk BCC; setting: secondary
care with outpatients from a single hospital in France; intervention: radiotherapy; comparison: SE (with or without frozen section margin
control). bDowngraded two levels for very serious imprecision due to very wide 95% CI (although excludes 1, there is a > 100-fold differ-
ence). cDowngraded one level for serious indirectness (outcome outside our prespecified timepoints) and downgraded one level for serious
imprecision as only a single study with a small sample size. dDowngraded one level for serious risk of bias as unable to blind truly owing to
the nature of interventions. eThree-point scale: bad; fair; good. fThree-point scale of scar appearance: bad, clearly marked, slightly visible.
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Table 4 Methyl aminolaevulinate photodynamic therapy (MAL-PDT) vs. surgical excision (SE) for low-risk basal cell carcinoma (BCC)a
Outcomes








(GRADE) CommentsRisk with SE Risk with MAL-PDT







Study population RR 118
(109–127)
309 (2 RCTs) ⊕⊕⊕⊝
MODERATEc
Participant-rated






Study population RR 187 (154–226) 256 (2 RCTs) ⊕⊕⊕⊝
MODERATEc
Observer-rated














Early treatment failure Study population RR 666 (122–3641) 173 (2 RCTs) ⊕⊕⊕⊝
MODERATEf11/1000 77/1000
(14–419)
AE, adverse event; CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomized
controlled trial; RR, risk ratio. aPatient or population: adults with low-risk BCC; setting: secondary care with outpatients from hospitals in
Brazil, the UK, Germany, Switzerland and Australia; intervention: MAL-PDT; comparison: SE. bDowngraded two levels for very serious impre-
cision owing to very wide 95% CI (although excludes 1, there is a > 100-fold difference). cDowngraded one level for serious risk of bias as
unable to blind truly owing to the nature of interventions. dFour-point scale: poor (extensive occurrence of scarring, atrophy or induration);
fair (slight-to-moderate occurrence of scarring, atrophy or induration); good (no scarring, atrophy or induration, and moderate redness or
increase in pigmentation vs. adjacent skin); excellent (no scarring, atrophy or induration, and slight or no redness or change in pigmentation
vs. adjacent skin). eDowngraded two levels for very serious imprecision as very wide 95% CI, indicating the possibility of important benefit
or harm. fDowngraded one level for serious imprecision due to small sample size and wide 95% CI.
Table 5 Aminolaevulinic acid photodynamic therapy (ALA-PDT) vs. surgical excision (SE) for low-risk basal cell carcinoma (BCC)a
Outcomes







(GRADE) CommentsRisk with SE Risk with ALA-PDT
Recurrence at 3 years Study population RR 1087
(263–4495)





Recurrence at 5 years Study population RR 1191
(290–4895)





Cosmetic outcome No study addressed this outcome NE – – –
Pain No study addressed this outcome NE – – –




CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NE, not estimable; RCT, randomized
controlled trial; RR, risk ratio. aPatient or population: adults with low-risk BCC; setting: secondary care with outpatients from a single-centre
in the Netherlands; intervention: ALA-PDT; comparison: SE. bDowngraded one level for serious imprecision as only a single study with a
small sample size and a wide 95% CI. cDowngraded two levels for very serious imprecision as very wide 95% CI, indicating the possibility
of important benefit or harm.
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(n = 20/37); RR 172, 95% CI 126–234 (moderate-certainty
evidence)].
Discussion
This systematic review included the full spectrum of interven-
tions for primary BCC by including 52 RCTs (52 compar-
isons) of varying methodological quality. Overall, the quantity
of research on interventions for BCC has doubled and quality
has improved since our 2007 update,37 with several RCTs
now publishing appropriate long-term follow-up data. Many
included studies still yield low- or moderate-certainty evidence
that should be interpreted with caution.
Surgery remains the most effective treatment modality for
BCC in terms of reducing recurrences, and there may be a
slightly reduced recurrence rate with MMS than with SE; how-
ever, the 95% CI also includes the possibility of both increased
risk and no difference between treatments (low-certainty evi-
dence). With regard to improvement of participant- and
observer-rated cosmetic outcomes, there may be little-to-no
difference between MMS and SE (low-certainty evidence);
however, no raw trial data were available for this outcome.
Radiotherapy is effective but probably worse than surgery
(under frozen section margin control) in terms of the number
of good cosmetic outcomes (moderate-certainty evidence).
Radiotherapy may also lead to increased recurrence vs. SE
(low-certainty evidence) and is therefore best reserved for
tumours not amenable to surgery. Three other RCTs assessed
radiotherapy against other interventions (see full review).7
These were all conducted over 20 years ago and, as techniques
and protocols have developed over time, the outcomes may
not be reflective of current-day radiotherapy outcomes. There-
fore, new studies comparing radiotherapy against other inter-
ventions are needed.
Nonsurgical treatments are less effective than surgical treat-
ments, but the evidence suggests that recurrence rates are
acceptable and they are important options to offer patients.
Imiquimod probably results in more recurrences than SE
(moderate-certainty evidence) and there is probably little-to-
no difference between groups in the number of participant-
rated good/excellent cosmetic outcomes (low-certainty evi-
dence). However, compared with SE, imiquimod may increase
Table 6 Imiquimod cream vs. methyl aminolaevulinate photodynamic therapy (MAL-PDT) for low-risk basal cell carcinoma (BCC)a
Outcomes












Study population RR 044
(032–062)













































CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomized controlled trial;
RR, risk ratio. aPatient or population: adults with low-risk BCC; setting: secondary care with outpatients from seven hospitals in the Nether-
lands; intervention: 5% imiquimod cream; comparison: MAL-PDT. bDowngraded one level for serious imprecision as only a single study with
a small sample size. cFour-point scale (poor, fair, good, excellent). dDowngraded one level for serious imprecision as only a single study with
a small sample size and a wide 95% CI.
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the number of observer-rated good/excellent cosmetic out-
comes (low-certainty evidence).
Moderate-certainty evidence indicates that imiquimod prob-
ably leads to fewer recurrences than MAL-PDT and there is
probably little-to-no difference between these treatments in
terms of observer-rated good/excellent cosmetic outcomes
(participant-rated cosmetic outcomes were not measured in
this comparison). MAL-PDT may result in more recurrences at
3 years than SE (low-certainty evidence; no useable data for
measurement at 5 years) but probably increases the number
of good/excellent cosmetic results (moderate-certainty evi-
dence).
The majority of studies were performed on low-risk his-
tological BCCs, located on low-risk sites, the results of
which are probably not applicable to high-risk tumours.
Only four studies looked at high-risk histological subtypes,
and three studies looked at BCCs at high-risk facial sites.
More studies or subgroup analyses are required for mor-
phoeic tumours.
The strengths of this review include our comprehensive,
systematic search strategy that aimed to include all relevant
studies, irrespective of language or publication status. Addi-
tionally, we conducted this review according to the rigorous
standards of the Cochrane Collaboration, including assessing
the risk of bias using the Cochrane risk-of-bias framework and
assessing the quality of evidence using the GRADE approach.
Most of the evidence for the outcomes presented for each of
the interventions has come from relatively small, single stud-
ies, which meant that meta-analysis was largely not possible.
The majority of these single studies were multicentre, but
many were limited by small sample sizes, and consequently,
many of the outcomes reported in this review have wide CIs.
This means that there is a large amount of imprecision in the
results, and therefore several of our results are of low-certainty
evidence, which threatens their external validity and repro-
ducibility. A further limitation of our review is that currently
there are no formally agreed core outcome sets for BCC clini-
cal trials – a task that is currently in progress.69 Consensus on
how to measure outcomes such as recurrence (e.g. clinically
or histopathologically) and cosmetic outcomes, as well as the
optimal timepoint, will improve our ability to assess the rela-
tive benefits and harms of interventions for BCC. Future trials
of BCC should register their trial prospectively and report ran-
domization, blinding and all outcomes according to CONSORT
criteria.70 Ideally, all BCC trials should include follow-up of
recurrences to 5 years.
Table 7 Imiquimod cream vs. fluorouracil (5-FU) cream for low-risk basal cell carcinoma (BCC)a
Outcomes
















Study population RR 068
(047–099)







Study population RR 062
(044–087)







Study population RR 107
(090–126)
377 (1 RCT) ⊕⊕⊕⊝
MODERATEb
Observer-rated






Study population RR 146
(089–238)




















CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomized controlled trial;
RR, risk ratio. aPatient or population: adults with low-risk BCC; setting: secondary care with outpatients from seven hospitals in the Nether-
lands; intervention: imiquimod cream; comparison: 5-FU cream. bDowngraded one level for serious imprecision as only a single study with
a small sample size. cFour-point scale: poor; fair; good; excellent. dDowngraded one level for serious imprecision as only a single study with
a small sample size and a wide 95% CI. eDowngraded two levels for very serious imprecision as very wide 95% CI, indicating the possibility
of important benefit or harm.
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